- Home
- RARE vs IFS Comparison
RARE vs IFS Comparison
Compare RARE & IFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- IFS
- Stock Information
- Founded
- RARE 2010
- IFS 1897
- Country
- RARE United States
- IFS Peru
- Employees
- RARE N/A
- IFS N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- IFS Commercial Banks
- Sector
- RARE Health Care
- IFS Finance
- Exchange
- RARE Nasdaq
- IFS Nasdaq
- Market Cap
- RARE 3.5B
- IFS 4.0B
- IPO Year
- RARE 2014
- IFS 2019
- Fundamental
- Price
- RARE $39.91
- IFS $37.26
- Analyst Decision
- RARE Strong Buy
- IFS Buy
- Analyst Count
- RARE 15
- IFS 1
- Target Price
- RARE $90.53
- IFS $30.00
- AVG Volume (30 Days)
- RARE 1.1M
- IFS 233.8K
- Earning Date
- RARE 07-31-2025
- IFS 08-13-2025
- Dividend Yield
- RARE N/A
- IFS 2.50%
- EPS Growth
- RARE N/A
- IFS 70.43
- EPS
- RARE N/A
- IFS 3.84
- Revenue
- RARE $590,689,000.00
- IFS $1,334,218,842.00
- Revenue This Year
- RARE $18.94
- IFS N/A
- Revenue Next Year
- RARE $28.93
- IFS $8.71
- P/E Ratio
- RARE N/A
- IFS $9.56
- Revenue Growth
- RARE 33.46
- IFS 25.66
- 52 Week Low
- RARE $29.59
- IFS $21.40
- 52 Week High
- RARE $60.37
- IFS $38.65
- Technical
- Relative Strength Index (RSI)
- RARE 65.02
- IFS 64.17
- Support Level
- RARE $35.51
- IFS $37.09
- Resistance Level
- RARE $38.19
- IFS $38.65
- Average True Range (ATR)
- RARE 1.58
- IFS 0.79
- MACD
- RARE 0.20
- IFS 0.11
- Stochastic Oscillator
- RARE 98.43
- IFS 78.83
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About IFS Intercorp Financial Services Inc.
Intercorp Financial Services Inc is a provider of banking, insurance, wealth management services and payments for retail customers and commercial clients in Peru. The company has four operating segments; the Banking segment includes Mainly loans, credit facilities, deposits, and current accounts, the Insurance segment provides life annuity products with single-premium payment and conventional life insurance products and other retail insurance products, the Wealth Management segment provides brokerage and investment management services. Its geographical segments include Peru and Panama.